TY - JOUR
T1 - Clonal haematopoiesis of indeterminate potential and impaired kidney function-A Danish general population study with 11 years follow-up
AU - Larsen, Morten K
AU - Skov, Vibe
AU - Kjaer, Lasse
AU - Møller-Palacino, Natascha A
AU - Pedersen, Rasmus K
AU - Andersen, Morten
AU - Ottesen, Johnny T
AU - Cordua, Sabrina
AU - Poulsen, Henrik E
AU - Dahl, Morten
AU - Knudsen, Trine A
AU - Eickhardt-Dalbøge, Christina Schjellerup
AU - Koschmieder, Steffen
AU - Pedersen, Kasper M
AU - Çolak, Yunus
AU - Bojesen, Stig E
AU - Nordestgaard, Børge G
AU - Stiehl, Thomas
AU - Hasselbalch, Hans C
AU - Ellervik, Christina
N1 - © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2022/11
Y1 - 2022/11
N2 - The myeloproliferative neoplasms are associated with chronic kidney disease but whether clonal haematopoiesis of indeterminate potential (CHIP) is associated with impaired kidney function is unknown. In the Danish General Suburban Population Study (N = 19 958) from 2010 to 2013, 645 individuals were positive for JAK2V617F (N = 613) or CALR (N = 32) mutations. Mutation-positive individuals without haematological malignancy were defined as having CHIP (N = 629). We used multiple and inverse probability weighted (IPW)-adjusted linear regression analysis to estimate adjusted mean (95% confidence interval) differences in estimated glomerular filtration rate (eGFR; ml/min/1.73 m2 ) by mutation status, variant allele frequency (VAF%), blood cell counts, and neutrophil-to-lymphocyte ratio (NLR). We performed 11-year longitudinal follow-up of eGFR in all individuals. Compared to CHIP-negative individuals, the mean differences in eGFR were -5.6 (-10.3, -0.8, p = .02) for CALR, -11.9 (-21.4, -2.4, p = 0.01) for CALR type 2, and -10.1 (-18.1, -2.2, p = .01) for CALR with VAF ≥ 1%. The IPW-adjusted linear regression analyses showed similar results. NLR was negatively associated with eGFR. Individuals with CALR type 2 had a worse 11-year longitudinal follow-up on eGFR compared to CHIP-negative individuals (p = .004). In conclusion, individuals with CALR mutations, especially CALR type 2, had impaired kidney function compared to CHIP-negative individuals as measured by a lower eGFR at baseline and during 11-year follow-up.
AB - The myeloproliferative neoplasms are associated with chronic kidney disease but whether clonal haematopoiesis of indeterminate potential (CHIP) is associated with impaired kidney function is unknown. In the Danish General Suburban Population Study (N = 19 958) from 2010 to 2013, 645 individuals were positive for JAK2V617F (N = 613) or CALR (N = 32) mutations. Mutation-positive individuals without haematological malignancy were defined as having CHIP (N = 629). We used multiple and inverse probability weighted (IPW)-adjusted linear regression analysis to estimate adjusted mean (95% confidence interval) differences in estimated glomerular filtration rate (eGFR; ml/min/1.73 m2 ) by mutation status, variant allele frequency (VAF%), blood cell counts, and neutrophil-to-lymphocyte ratio (NLR). We performed 11-year longitudinal follow-up of eGFR in all individuals. Compared to CHIP-negative individuals, the mean differences in eGFR were -5.6 (-10.3, -0.8, p = .02) for CALR, -11.9 (-21.4, -2.4, p = 0.01) for CALR type 2, and -10.1 (-18.1, -2.2, p = .01) for CALR with VAF ≥ 1%. The IPW-adjusted linear regression analyses showed similar results. NLR was negatively associated with eGFR. Individuals with CALR type 2 had a worse 11-year longitudinal follow-up on eGFR compared to CHIP-negative individuals (p = .004). In conclusion, individuals with CALR mutations, especially CALR type 2, had impaired kidney function compared to CHIP-negative individuals as measured by a lower eGFR at baseline and during 11-year follow-up.
KW - Calreticulin/genetics
KW - Clonal Hematopoiesis/genetics
KW - Denmark/epidemiology
KW - Follow-Up Studies
KW - Humans
KW - Janus Kinase 2/genetics
KW - Kidney/metabolism
KW - Mutation
KW - Thrombocythemia, Essential/genetics
UR - http://www.scopus.com/inward/record.url?scp=85136518495&partnerID=8YFLogxK
U2 - 10.1111/ejh.13845
DO - 10.1111/ejh.13845
M3 - Journal article
C2 - 36054308
SN - 0902-4441
VL - 109
SP - 576
EP - 585
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 5
ER -